Pulmonary Arterial Hypertension Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Pulmonary Arterial Hypertension remains an active clinical development field. Development is moving beyond single surrogate measures toward integrated cardiometabolic, renal and clinical-outcome evidence, with convenience and persistence becoming major differentiators. The PatSnap evidence set used here contains 382 matched trial records and 425 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| ChiCTR2600128197 | Intervention not normalized | Not Applicable; Recruiting | Beijing Chao-Yang Hospital | China | T1 mapping、T2 mapping、PREFUL MRI ventilation-perfusion parameters and other magnetic resonance parameters (Before or within 3 days after the right heart catheterization procedure); Death incident (The 6th, 12th, 18th, 24th, 30th, and 36th month) | 2030-06-01 |
| NCT07700303 | Intervention not normalized | Not Applicable; Not yet recruiting | University of Alberta | Canada | Change in Mean Pulmonary Arterial Pressure (mPAP) From Baseline to 24 Weeks (Baseline to 24 weeks) | 2028-03-30 |
| NCT07697235 | Intervention not normalized | Not Applicable; Not yet recruiting | Les Hopitaux Universitaires de Strasbourg | Geography not listed | Change from baseline in M1/M2 macrophage polarization markers in peripheral blood mononuclear cells (PBMCs) (From baseline to end of treatment (12 weeks)) | 2029-03-01 |
| ChiCTR2600127567 | Intervention not normalized | Not Applicable; Recruiting | Huzhou Central Hospital | China | Expression levels of NAT10, LDHA and HIF-1α in lung tumor tissues | 2029-12-31 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy (Phase 3): the indexed record reports Change From Baseline in Peak VO2 Assessed by CPET(Median) = 0.929 mL/kg/min (Full Range, -0.73 to 2.59); Change From Baseline in Peak VO2 Assessed by CPET(Median) = -1.953 mL/kg/min (Full Range, -3.46 to -0.45); -.
- A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (TROPOS Study) (Phase 2): the indexed record reports -; Change From Baseline in PVR (Pulmonary Vascular Resistance)(Median) = -73.0 dyn*sec/cm^5 (Full Range, -305.2 to 191.0); Change From Baseline in PVR (Pulmonary Vascular Resistance)(Median) = -15.3 dyn*sec/cm^5 (Full Range, -511 to 1809).
- An Open-label, Prospective, Single Centre Study of the Effects of Riociguat on RIght VEntricular Size and Function in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension (Phase 4): the indexed record reports Change in RV (Right Ventricular) Area(Mean) = -6.00 cm^2 (Standard Deviation, 3.80); Change in RV (Right Ventricular) Area(Mean): Mean Difference (Final Values) = -6.00(95% CI, -7.42 to -4.58), P-Value = <0.001; Change in RV (Right Ventricular) Area(Mean): Mean Difference (Final Values) = -6.00(95% CI, -7.42 to -4.58), P-Value = <0.001.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including The selected trials include interventions that are not yet normalized to an asset record. Company & Deal Intelligence records identify sponsor context for Beijing Chao-Yang Hospital, University of Alberta, Les Hopitaux Universitaires de Strasbourg, Huzhou Central Hospital. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Active-comparator trials on top of contemporary standard of care.
- Hard cardiovascular, kidney or liver outcomes linked to earlier biomarker change.
- Evidence in underrepresented populations and patients with multiple comorbidities.
- Durability, adherence and post-discontinuation outcomes.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Pulmonary Arterial Hypertension has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
